MY MAN! Quite the compilation! I saved this post for future reference. Thanks so much, Fate !!!
11
u/Saabil
Than you very much for sharing
6
u/Fate-it-is
ChatGPT created Microsoft Excel file, but I’m not sure it can be opened in Reddit. I’ll try to make a new post and hope it works.
5
u/Fate-it-is
Yes — here is a clean chart of the main companies tied to Dr. Henry Ji and the scientific / intellectual-property focus of each. I’ve split it into direct affiliations and indirect / transactional ecosystem ties so it is easier to follow.
Henry Ji / SRNE ecosystem chart
Company / Entity Ji affiliation Direct or indirect Scientific / IP focus Key basis Sorrento Therapeutics (SRNE) Co-founder; director since 2006; CEO/President since 2012; Chairman since 2017 Direct Core platform company built around the G-MAB fully human antibody library, plus immuno-oncology, ADCs, cell therapies, oncolytic virus, and lymphatic delivery platforms Sorrento SEC filings say Ji co-founded Sorrento and that the G-MAB Library was initially invented by Henry Ji; filings also describe G-MAB, ADC, DAR-T, Seprehvec, and Sofusa as proprietary platforms.  Scilex Holding (SCLX) Chairman / Executive Chair; also previously CEO of Scilex Pharmaceuticals Direct Commercial-stage non-opioid pain platform; owns/controls brands such as ZTlido, ELYXYB, and through subsidiary Semnur, SEMDEXA / SP-102 Scilex’s official bio and SEC filings describe Ji as Chairman/Executive Chair and former CEO of Scilex Pharma; Scilex filings identify the product/IP ownership structure.  Semnur Pharmaceuticals Treasurer, Secretary, board member since inception; tied through Scilex Direct / controlled via Scilex SP-102 / SEMDEXA: non-opioid epidural viscous-gel dexamethasone product for sciatica/radicular pain; patent family disclosed as extending to 2036 in company materials Scilex SEC filings say Ji has served as Semnur’s Treasurer, Secretary, and director since inception; Scilex materials describe Semnur and SP-102/SEMDEXA IP.  Scilex Pharmaceuticals Board member since 2016; served as CEO 2016–2019 Direct Pain-product operating subsidiary; key marketed asset ZTlido and development programs including SP-103 Scilex SEC filings describe Ji’s operating role at Scilex Pharma.  Vivasor Holding / Vivasor, Inc. CEO Direct Not a classic legacy SRNE therapeutic platform in the same way as G-MAB/Scilex, but clearly part of Ji’s newer post-SRNE affiliated corporate network Recent Scilex/Semnur SEC filings state Ji currently serves as CEO of Vivasor Holding Company and Vivasor, Inc.  TNK Therapeutics Sorrento-controlled / Ji-linked through SRNE Direct through SRNE Cell therapy / CAR-T–related platform; Sorrento filings describe immuno-cellular therapy programs and TNK’s role in contributed CAR-related IP Sorrento SEC filings refer to TNK and contributed proprietary CAR constructs/IP in the Celularity transaction.  Sofusa / Sofusa Lymphatic Delivery System Sorrento-acquired platform under Ji-led SRNE Direct through SRNE Lymphatic drug delivery using proprietary microneedle / microfluidic delivery into lymphatic and systemic capillaries Sorrento 10-K and Sofusa materials describe it as an acquired proprietary lymphatic drug-delivery platform.  Virex Health Acquired by Sorrento Direct through SRNE Diagnostics using enzymatic + electrochemical amplification for very low-level analyte detection Acquisition announcement describes Virex’s proprietary electrochemical/enzymatic amplification technology.  Levena / Concortis SRNE platform companies / subsidiaries Direct through SRNE ADC technology: linker-payload / conjugation know-how used in antibody-drug conjugates Sorrento filings describe ADCs as a core proprietary platform within the Ji/SRNE ecosystem.  Virttu Biologics / Seprehvec platform SRNE-controlled platform Direct through SRNE Oncolytic virus program, including Seprehvec Sorrento filings list Seprehvec/oncolytic virus as a proprietary platform.  Celularity Transactional / strategic tie; SRNE and TNK contributed IP in exchange for equity Indirect Placental / regenerative / cell therapy company; key tie is that SRNE/TNK contributed certain CAR-related IP and received Celularity equity Sorrento SEC filings state that Sorrento and TNK contributed certain proprietary CAR constructs and related IP to Celularity for Series A Preferred Stock.  NantCell / NantWorks / ImmunityBio ecosystem Collaboration, licensing, and later litigation/counterclaims Indirect Main tie appears to be antibody library / immunotherapy rights, not ownership control by Ji; later became part of the broader Nant/Sorrento disputes Sorrento’s older SEC filings reference an exclusive license agreement with NantCell; ImmunityBio later disclosed claims tied to Sorrento’s antibody-library agreement.  OQORY, Inc. Ji signed as Chairman of the Board in transaction materials Indirect / newer affiliation Public filings tie Ji to board leadership, but the scientific/IP profile is less clearly established in the sources I checked than for SRNE/Scilex/Semnur Vincerx-related filings show Ji signing for OQORY as Chairman and for Vivasor as CEO. 
The IP map in one glance
If you want the scientific/IP families rather than just the company names, the network looks like this:
IP / science family Main company t
4
u/Comfortable-Heart529
AI or anyone else can paint any sineros but sadly all roads lead to the brutal truth, the PPS
3
u/Early-Blueberry838
great work. where is Oorqy?
3
u/Firm_Ad_8895
Great job
3
u/SRNEInvestor
Did ChatGPT happen to find a single investor that made money from any of these ventures other than Henry? That’s a question I would love to see answered.